Complications of Implantable Cardioverter Defibrillator and Their Potential Risk Factors in Patients with Hypertrophic Cardiomyopathy

被引:0
|
作者
Goudarzi, Mohammad Taghi Hedayati [1 ]
Moradi, Maryam [2 ]
Abrotan, Saeed [1 ]
Saravi, Mehrdad [2 ]
Shirafkan, Hoda [3 ]
Irilouzadian, Rana [4 ]
Omran, Hossein Salehi [1 ]
机构
[1] Babol Univ Med Sci, Rohani Hosp, Sch Med, Dept Cardiol, Babol, Iran
[2] Babol Univ Med Sci, Fac Med, Dept Cardiol, Babol, Iran
[3] Babol Univ Med Sci, Hlth Res Inst, Social Determinants Hlth Res Ctr, Babol, Iran
[4] Iran Univ Med Sci, Burn Res Ctr, Tehran, Iran
关键词
SUDDEN-DEATH; TASK-FORCE; THERAPY; POPULATION; PREVENTION; EFFICACY; OUTCOMES; SOCIETY;
D O I
10.1155/2023/4552100
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Hypertrophic cardiomyopathy (HCM) has different complications such as cardiac arrhythmia and sudden cardiac death (SCD). Insertion of an implantable cardioverter defibrillator (ICD) is recommended for HCM patients who are at high risk of SCD and malignant arrhythmias, despite having their own potential complications. Hypothesis. We aimed to investigate the prevalence of different complications of ICD insertion and the impact of the potential influential baseline characteristics in a one-year follow-up period. Methods. This was a retrospective study with a total of 71 HCM patients with ICD insertion. We evaluated the prevalence of different complications of ICD implantation and the impact of baseline characteristics on the occurrence of ICD complications using multivariate regression analysis in three 4-month periods. Results. In a one-year follow-up, 13 patients (18.3%) experienced at least one of the complications including pneumothorax, lead failure, ICD infection, inappropriate shocks, perforation, and upper limb deep vein thrombosis (DVT) with no mortality. Inappropriate shocks were reported as the most common (11.3%) complication during this period, with a gradual increase in the second (4.2%) and third (5.6%) follow-up sessions. Among all of the baseline characteristics that were investigated in this study, a positive history of hypertension was the only risk factor with significant impact on the occurrence of complications (P = 0.01). Conclusion. We demonstrated the occurrence of complications during a one-year follow-up as 18.3% in HCM patients with ICD insertion. A positive history of hypertension was the only baseline characteristic affecting the occurrence of complications, and inappropriate shocks were the most common complication.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Circadian rhythm of appropriate implantable cardioverter defibrillator discharges in patients with hypertrophic cardiomyopathy
    Kiernan, Thomas J.
    Weivoda, Peggy L.
    Somers, Virend K.
    Ommen, Steve R.
    Gersh, Bernard J.
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2008, 31 (10): : 1253 - 1258
  • [22] Implantable cardioverter-defibrillator in pregnant women with hypertrophic cardiomyopathy
    Cordeiro de Paula, Leonardo Jorge
    Ribeiro, Henrique Barbosa
    de Oliveira Junior, Roberto Marcio
    da Silva, Katia Regina
    REVISTA BRASILEIRA DE CIRURGIA CARDIOVASCULAR, 2010, 25 (03): : 406 - 409
  • [23] Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: experience of a tunisian center
    Mezni, M. F. Mohamed Fares
    Haggui, A.
    Jdaida, B.
    Ben Mansour, N.
    Dahmani, R.
    Lahidheb, D.
    Fehri, W.
    Haouala, H.
    EUROPEAN JOURNAL OF HEART FAILURE, 2015, 17 : 59 - 59
  • [24] Strength of clinical indication and therapeutic impact of the implantable cardioverter defibrillator in patients with hypertrophic cardiomyopathy
    Fumagalli, Carlo
    De Filippo, Valentina
    Zocchi, Chiara
    Tassetti, Luigi
    Marra, Martina Perazzolo
    Brunetti, Giulia
    Baritussio, Anna
    Cipriani, Alberto
    Bauce, Barbara
    Carrassa, Gianmarco
    Maurizi, Niccolo
    Zampieri, Mattia
    Calore, Chiara
    De Lazzari, Manuel
    Berteotti, Martina
    Pieragnoli, Paolo
    Corrado, Domenico
    Olivotto, Iacopo
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2022, 353 : 62 - 67
  • [25] Is subcutaneous implantable cardioverter-defibrillator testing effective and safe for patients with hypertrophic cardiomyopathy?
    Qin, Fen
    Liu, Qiming
    Liu, Zhenjiang
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 246 : 54 - 54
  • [26] Supraventricular Arrhythmia Induction by an Implantable Cardioverter Defibrillator in a Patient with Hypertrophic Cardiomyopathy
    Akbarzadeh, Fariborz
    Kazemi, Babak
    Pourafkari, Leili
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2010, 33 (03): : 372 - 376
  • [27] Implantable cardioverter defibrillator in hypertrophic cardiomyopathy: Time to avoid unnecessary procedure
    Limongelli, Giuseppe
    Monda, Emanuele
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2022, 355 : 30 - 31
  • [28] Implantable cardioverter-defibrillator therapy in hypertrophic cardiomyopathy: A SIMPLE substudy
    Vamos, Mate
    Healey, Jeff S.
    Wang, Jia
    Connolly, Stuart J.
    Mabo, Philippe
    Van Erven, Lieselot
    Kautzner, Josef
    Glikson, Michael
    Neuzner, Jorg
    O'Hara, Gilles
    Vinolas, Xavier
    Gadler, Frederik
    Hohnloser, Stefan H.
    HEART RHYTHM, 2018, 15 (03) : 386 - 392
  • [29] TACHYCARDIA SENSING FAILURE OF AN IMPLANTABLE CARDIOVERTER DEFIBRILLATOR IN A PATIENT WITH HYPERTROPHIC CARDIOMYOPATHY
    GRUBB, BP
    DURZINSKY, D
    TEMESYARMOS, P
    HAHN, H
    ELLIOTT, L
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1992, 15 (06): : 845 - 848
  • [30] Survival after cardiac arrest in patients with hypertrophic cardiomyopathy: Role of the implantable cardioverter-defibrillator
    Borggrefe, MM
    McKenna, WJ
    CIRCULATION, 1999, 100 (18) : 76 - 76